A Step-wise Approach for Transfer of Immunogenicity Assays during Clinical Drug Development
- 238 Downloads
We designed a three-step statistical approach to transfer bioanalytical assays (ELISA and Biacore) which evaluates the (1) average equivalence between the two labs (2) concordance in individual sample results between the two labs, and (3) long-term stability of assay performance. Each experimental design evaluated the contribution of four critical variables to the overall variability. Two lots of each variable were examined in a controlled experiment. The variables tested for ELISA were analyst, plate washer, biotinylated-therapeutic protein, and streptavidin–horseradish peroxidase; and for Biacore were analyst, instrument, chip lot, and conjugation chemistry reagent lots. Equivalence in the mean signal to noise (S/N) or mean relative units (RU) between the two labs was established through statistical evaluation of the assay performance characteristics across multiple assay variables. Concordance between the two labs in the individual sample results was subsequently verified both quantitatively and qualitatively. The long-term maintenance of assay stability was monitored by performance testing of a predefined set of samples which were prepared in sufficient quantities to last several years. The process of method validation for biomarker testing in clinical trials is to analyze the variability of the assay performance. However, different factors contribute to this variability and need to be evaluated when the method is transferred to another site/lab. Lack of understanding the critical variables can potentially result in unexpected problems and delays. The three-step statistical approach of assay transfer provides a robust process for transferring complex biological assays.
Key wordsbiacore bioanalytical concordance ELISA method transfer robustness
coefficient of concordance correlation
streptavidin-conjugated horse radish peroxidase
signal to noise ratio
We thank the scientists at Amgen (Sarah Hoofring, Jim Lofgren, and Michelle Wu) for performing the assays; Marta Starcevic, Troy Barger, and Dan Mytych for helpful comments and experiences from previous assay transfer methods. This work was done at Amgen and all the authors hold company stock.
- 1.Benson C. Guidance for Industry and FDA Staff: Recommendations for Clinical Laboratory Improvement Amendments of 1988 (CLIA) Waiver Applications for Manufacturers of In Vitro Diagnostic Devices. www.fda.gov; 2008.
- 2.Bland X, Altman X. Statistical methods for assessing agreement between two methods for clinical measurement. Lancet. 1986;8:307–10.Google Scholar
- 4.FDA. Question to the Sponsor. http://www.fda.gov/CbER/products/pentacel/pentacel060707L.htm; 2007.